Renovo Plc. | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Renovo Plc.

An SI Board Since September 2006

Posts	SubjectMarks	Bans	Symbol
40	5	0	RNVO.L

Emcee: nigel bates	Type: Moderated

Introduction Market Data Compact

"Renovo is the world leader in scar prevention and reduction research, developing pharmaceutical products to prevent and reduce scarring in the skin, blood vessels, eyes, nerves, internal organs, tendons and ligaments.

Our pipeline is extensive and includes four products in phase II clinical development, a further four advanced pre-clinical candidates and nine other pre-clinical candidates.

There is an estimated multi-billion dollar global market for anti-scarring drugs, and Renovo aims to be first to market with a scar prevention pharmaceutical drug in the US and Europe to capitalise on this huge, unmet market need..."
renovo.com

With the announcement of a successful PII for Juvista (human recombinant TG beta 3) -
Message 22856801
- it could be time to take them seriously.

Time for a thread, anyhow.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
40	(23rd November) Renovo Group plc (LSE : RNVO), the biopharmaceutical company dev	nigel bates	-	11/24/2010
39	Just listened to the JPM webcast, which I thought was impressive.	DewDiligence_on_SI	-	1/30/2008
38	They also said worst case the mole market is 2%. And realistically the keloid	keokalani'nui	-	12/13/2007
37	Ouch. >>I thought company gave a pretty good explanation why the protocol	nigel bates	-	12/13/2007
36	Analysts now having serious doubts about whether co has dose nailed down. Effec	keokalani'nui	-	12/13/2007
35	Looks like stock getting killed for J failing head and neck trial, but I thought	keokalani'nui	-	12/13/2007
34	Writeup in the New Scientist: newscientist.com Nothing new, but a mention of th	nigel bates	-	9/20/2007
33	STATISTICALLY SIGNIFICANT EFFICACY OF JUVISTA® DEMONSTRATED IN PHASE 2 TRIA	keokalani'nui	-	9/12/2007
32	28 August 2007 RENOVO GROUP PLC APPOINTMENT OF DR JOHN HUTCHISON AS CHIEF MEDI	nigel bates	-	8/29/2007
31	Renovo Group plc Issue of Equity Pursuant to the announcement made on 17 August	nigel bates	-	8/29/2007
30	I've made worse... ..and plenty of them. Dunno about the choice of partner	nigel bates	-	6/20/2007
29	One of the best calls ever, Nigel. Congrats. Super deal. But did rnvo choose m	keokalani'nui	-	6/20/2007
28	Royalty percentage "high teens" - >>...Some analysts expressed	nigel bates	-	6/20/2007
27	>>Love this one<< What I like is that the deal clearly didn't l	nigel bates	-	6/20/2007
26	The hot number(s) will be the royalty percentages - which I haven't got, as	nigel bates	-	6/20/2007
25	Seems like $75m is the new hot number. Nice.	kenhott	-	6/20/2007
24	Shire In-Licenses JUVISTA(R) (Human TGFbeta3) From Renovo BASINGSTOKE, England a	nigel bates	-	6/20/2007
23	Nice. Love this one.	keokalani'nui	-	4/17/2007
22	RENOVO ANNOUNCES POSITIVE PHASE II EFFICACY TRIAL RESULTS FOR PREVASCAR Renovo	nigel bates	-	4/17/2007
21	Thanks for the reminder.	keokalani'nui	-	3/5/2007
20	Eleven months back, they promised a licensing deal within the next 12 months. N	nigel bates	-	3/5/2007
19	Nice, thorough commentary by CEO. Thanks for the link.	keokalani'nui	-	1/19/2007
18	Annual report up on website - renovo.com	nigel bates	-	1/19/2007
17	TOTAL VOTING RIGHTS <pre>In conformity with the Transparency Directive	nigel bates	-	1/5/2007
16	The cosmeceuticals market has several things going for it from an investment sta	DewDiligence_on_SI	-	1/2/2007

Go to reply# or date (mm/dd/yy):